Symptoms in myeloproliferative neoplasms (MPNs) are diverse, often persistent, and frequently reduce quality of life. The most common complaints and their underlying reasons are summarized below in patient-friendly language, along with practical clues to help clinicians identify their causes.

Constitutional and systemic symptoms

• Fatigue and reduced stamina. The single most frequent symptom arises from chronic inflammation, anemia in some patients, and metabolic effects of the disease. Fatigue can be constant or worse on some days and often interferes with work and daily activities. [1][2]
• Night sweats, fever, and unintentional weight loss. Reflect systemic inflammation or advanced marrow activity (more common in myelofibrosis). These “B symptoms” (doctor shorthand for fever, sweats, weight loss) may signal higher disease activity and warrant closer evaluation. [1]

Microvascular and neurologic complaints

• Headache, lightheadedness, and visual disturbances. Small-vessel abnormalities and changes in blood viscosity can cause transient neurologic symptoms. These often improve when hematologic parameters are controlled. [2]
• Erythromelalgia (burning pain, redness, warmth in hands/feet). Caused by platelet-mediated microvascular dysfunction; classically relieved by cooling and improved by low-dose aspirin if safe in many patients. [1]

Skin and sensory symptoms

• Aquagenic pruritus (intense itching after warm baths/showers). A hallmark symptom in many patients with polycythemia vera and present across MPNs; thought to be mediated by inflammatory chemical signals and histamine-like pathways. It can be severe and disrupt sleep. [1]
• Neuropathic nerve-type sensations and paresthesia. Numbness, tingling, or “pins and needles” may occur from microvascular or treatment-related causes. [4]

Organ-related symptoms

• Early satiety, abdominal fullness, and left-upper-quadrant discomfort. Enlarged spleen (splenomegaly) or liver enlargement can compress the stomach or bowel, causing a reduced appetite and a feeling of fullness after eating small meals. These symptoms often fluctuate in relation to spleen size and respond to therapies that reduce splenic volume. [2]
• Bone and joint pain. Marrow expansion and local inflammation can produce deep, aching bone pain that varies by disease subtype and activity. [1]

Hemorrhagic and thrombotic events

Bleeding (easy bruising, mucosal bleeding) and thrombosis (DVT, stroke, unusual site clots) are both possible. Paradoxically, MPNs increase the risk of clotting while sometimes causing dysfunctional platelets that predispose to bleeding. Prior thrombosis is also a key marker of worse prognosis. [2][6]

Psychosocial and functional effects

Cognitive fog, trouble concentrating or thinking clearly, mood changes, and reduced quality of life. Persistent symptoms and uncertainty about disease course often lead to anxiety, depression, and impaired daily functioning, domains captured by modern symptom assessments. These issues are especially relevant in adolescents and young adults, who face additional psychosocial and fertility concerns. [3][4]

How symptoms are captured and why that matters

• Validated patient-reported tools (MPN-SAF/MPN-10 and the modified total symptom score) quantify severity and frequency, enabling standardized tracking over time and guiding treatment choices. Higher scores correlate with worse quality of life and often trigger treatment escalation or supportive interventions. [4]
• Symptoms often fluctuate; a single clinic visit may under- or overestimate burden. Regular, structured assessments are recommended by clinical guidelines to detect change and measure response to therapy. [2]

Overall, the symptoms of myeloproliferative neoplasms span physical, neurological, and psychosocial domains. Recognizing typical patterns and utilizing validated scores enhances care planning, facilitating the prioritization of interventions that reduce symptom burden and improve quality of life. [1][4]

Standardized symptom measurement converts subjective complaints into numbers we can track that can inform treatment decisions, track response, and facilitate comparison across clinics and trials. The MPN-SAF (also called the MPN-10 when reduced to core items) and its validated modified Total Symptom Score (TSS) are the most widely used tools for this purpose. [4][2]

How the tools work:

• The instruments are patient-reported: patients rate the severity of symptoms (e.g., fatigue, pruritus, night sweats, early satiety, bone pain, and concentration problems) over a recent recall period. Scores for individual items are summed to generate a total symptom burden measure (TSS). Higher totals indicate greater overall symptom burden. [4]
• The modified TSS validated by Langlais and colleagues demonstrates reliability and construct validity has been tested and shown to work well across MPN subtypes, making it suitable for routine clinical use and for comparing patient groups in research. [4]

Why routine measurement matters

• Objective scores reveal hidden or under-reported symptoms, quantify change over time, and support shared decisions about escalating therapy (for example, starting a JAK inhibitor or switching cytoreductive agents) or adding focused supportive care. Guidelines now recommend baseline symptom assessment and periodic reassessment as part of standard management of MPN. [2][1]
• Using the same tool at each visit makes it possible to detect gradual worsening or improvement that a brief clinic interview might miss; this is particularly important because symptoms often fluctuate from day to day. [4]

Practical features that clinicians and clinics adopt

• Baseline assessment at diagnosis or first specialist visit, with repeat scoring at regular intervals (for example, every clinic visit while treatment is changing, then on a scheduled follow-up cadence). Exact timing is individualized per guidelines and clinical context. [2]
• Item-level review to identify targetable problems (severe pruritus → consider antihistamines/interferon/other measures; high early-satiety score → assess spleen size and consider splenic-directed therapy). [1]
• Integration with electronic records and symptom registries where available, enabling longitudinal tracking and quality-improvement efforts. [4]

Special considerations

• Tools may need adaptation for adolescents/young adults (A/YAs) or for patients with comorbid conditions (for example, chronic kidney disease) that add symptom overlap. Clinicians should interpret scores within the broader clinical context and consider complementary assessments to address psychosocial needs. [3][6]
• Symptom-directed trials and pragmatic studies are increasingly using MPN-TSS as a primary or secondary endpoint. Therefore, routine use aligns clinical practice with the evidence base and helps patients access therapies that have been shown to improve patient-reported outcomes. [4][5]

Symptoms overlap across myeloproliferative neoplasms (MPNs), but specific patterns tend to predominate in each subtype. Noting which symptoms cluster together helps clinicians recognise disease activity and target treatments appropriately.

Myelofibrosis (MF) — constitutional and splenic symptoms dominate

Myelofibrosis commonly causes marked fatigue, night sweats, weight loss, fever, and significant splenomegaly. The enlarged spleen can cause early satiety, abdominal fullness, and discomfort in the left upper quadrant. Areas of spleen tissue that lose blood supply (very painful) or rapid enlargement can lead to acute pain. Constitutional symptoms reflect a high inflammatory burden and marrow failure/expansion, and are a significant reason for symptom-directed therapy in MF. [2][1]

Typical MF symptom cluster (frequent, often severe)

• Fatigue and reduced exercise tolerance. [2]
• Night sweats, fevers, weight loss. [1]
• Marked splenomegaly → early satiety, abdominal fullness, left-upper-quadrant pain. [2]

Polycythemia vera (PV) — microvascular and pruritic symptoms are common

PV often presents with aquagenic pruritus (intense itching after hot baths/showers), erythromelalgia (burning/redness of hands or feet), headache, visual disturbances, and a ruddy complexion. These symptoms reflect microvascular dysfunction and increased blood viscosity; they frequently respond to measures that reduce cell counts or platelet activity (for example, phlebotomy and antiplatelet therapy). [1][2]

Common PV patterns

• Aquagenic pruritus (sometimes disabling). [1]
• Burning pain/redness in extremities (erythromelalgia), transient visual symptoms, and headaches. [2]

Essential thrombocythemia (ET) — microvascular and bleeding-related symptoms

ET typically produces headache, lightheadedness, visual blurring, and erythromelalgia, reflecting platelet-driven microvascular phenomena. Paradoxical bleeding (mucosal bleeding, easy bruising) can occur if platelet function is abnormal or extremely high platelet counts consume von Willebrand factor. Symptom severity varies widely; some people are minimally symptomatic, while others have frequent disabling microvascular complaints. [2][1]

ET-typical features:

• Microvascular symptoms (headache, transient visual disturbance, erythromelalgia). [2]
• Bleeding tendency in specific settings. [1]

Special-population considerations

• Adolescents and young adults (AYA): symptom profiles may include the usual physical complaints but with added psychosocial, fertility, and educational/vocational impacts that require tailored assessment and support. Validated tools may need adaptation for younger age groups. [3]
• Comorbid chronic kidney disease (CKD): CKD can amplify fatigue and other symptoms, and interact with bleeding/thrombotic risks—assessment should account for overlapping contributors to symptom burden. [6]

How subtype patterns guide action

• High early-satiety scores → correlate with spleen size and prompt consideration of splenic-directed therapy or JAK inhibitor when appropriate. [4]
• Predominant pruritus or erythromelalgia → consider cytoreductive or antiplatelet strategies and symptom-directed measures. [1]
• Fluctuating constitutional symptoms → monitor with serial MPN-TSS to judge treatment response. [4]
• Recognising these subtype-specific symptom clusters and measuring them systematically enables targeted interventions that reduce burden and improve quality of life. [2]

Symptom management in myeloproliferative neoplasms (MPNs) blends disease-directed therapy with focused supportive care. The goal is to reduce the clinical burden captured by validated symptom scores, improve daily functioning, and address drivers that cause symptoms worse (for example, splenomegaly, inflammation, or comorbid disease). Management is individualized by MPN subtype, symptom pattern, age, comorbidity, and treatment goals. [2][1]

1. Disease-directed therapies that relieve symptoms

• JAK inhibitors (e.g., ruxolitinib): These are the medicines that calm overactive JAK signals to reduce symptoms. Strong evidence supports JAK inhibitors for reducing constitutional symptoms and spleen-related discomfort in myelofibrosis and for symptom relief in selected patients with polycythemia vera who are resistant/intolerant to first-line therapy. Symptom reductions are often measurable within weeks to months on validated TSS instruments. [2]
• Interferon (a long-acting form of interferon; fewer injections, including long-acting ropeginterferon): Interferon-based regimens can reduce symptom burden and offer disease-modifying potential in certain patients (younger adults, pregnancy considerations). Emerging long-acting preparations may provide durable symptom and hematologic control for selected patients. [2][5]
• Cytoreductive agents (hydroxyurea and alternatives): These are the medicines that lower high blood counts. For patients with high symptom-driven cell counts or microvascular symptoms (erythromelalgia), cytoreduction with hydroxyurea or interferon can help alleviate symptoms by reducing cell mass and platelet activity. Choice of agent balances efficacy, side-effect profile, and individual patient goals. [2]

2. Targeted symptom-directed treatments

• Pruritus (aquagenic or generalized): antihistamines, selective serotonin reuptake inhibitors, gabapentin, phototherapy, or cytoreductive options may be considered when severe; response varies, and a stepped approach is typically employed. [1]
• Erythromelalgia and microvascular pain: Low-dose aspirin often provides prompt relief by addressing platelet-related microthrombosis; persistent cases may benefit from cytoreductive therapy. Cooling measures and topical analgesia provide adjunctive relief. [1][2]
• Splenic discomfort and early satiety: JAK inhibitors reduce spleen volume and related symptoms in many patients; splenectomy or radiotherapy are reserved for refractory or complicated cases and carry significant risks that require specialist judgement. [2]

3. Non-pharmacologic and integrative strategies

• Exercise and graded physical activity, slowly increased through step-by-step activity, improve fatigue, mood, and functional capacity when tailored to the patient’s baseline tolerance. [5]
• Psychosocial support and cognitive behavioural approaches: address anxiety, depression, and mental symptoms that often accompany chronic symptom burden; integrate with medical care for the best effect. [1][5]
• Nutritional and sleep hygiene interventions: targeted measures for appetite loss, weight change, and sleep disturbance can reduce symptom severity and improve overall well-being. [5]

4. Comorbidity and population-specific considerations

• Chronic kidney disease (CKD): CKD amplifies fatigue and may modify bleeding/thrombotic risk; symptom management should account for renal function when selecting drugs and dosing. Collaboration with nephrology is useful for complex cases. [6]
• Adolescents and young adults (AYA): fertility, education/work disruption, and long-term psychosocial effects influence treatment choice; symptom tools may need age-appropriate framing and additional supportive services. [3]

5. Practical framework for choosing interventions

• Measure first, treat specifically. Use a validated symptom score (MPN-10/modified TSS) at baseline to identify the dominant problems and repeat at intervals to judge response. [4]
• Start with low-risk, high-yield measures. For many microvascular symptoms, a trial of low-dose aspirin or simple topical/cooling measures is appropriate while arranging disease-directed therapy as needed. [2]
• Escalate when scores or clinical status warrant step up treatment when scores get worse or symptoms limit daily life. High or worsening TSS, progressive splenomegaly, or poor quality of life usually justify specialist discussion about JAK inhibitor therapy, interferon, or alternative cytoreductive approaches. [2]

6. Guideline alignment and multidisciplinary care

• Clinical practice guidelines recommend routine symptom assessment, integrating symptom burden into treatment decisions, and multidisciplinary support (including hematology, symptom specialists, psychosocial services, and rehabilitation). Coordinated care ensures that symptom relief and disease control proceed in parallel. [2][1]

In summary, symptom relief in MPNs requires a layered strategy: validated measurement, targeted symptomatic therapies, disease-directed agents when indicated, and non-pharmacological supports adapted to comorbidities and life stage. Regular reassessment with the MPN-TSS enables an objective evaluation of benefit and guides the timely escalation or modification of therapy. [4][2]

A concise, action-oriented checklist helps turn symptom scores into care steps. Use the MPN-SAF/MPN-10 (or the validated modified TSS) at baseline and at every meaningful visit, then apply the items below to prioritize interventions and referrals. [4][2]

Assessment & monitoring

• Complete a validated symptom score (MPN-10 / modified TSS — a short checklist patients fill in) at diagnosis and routinely (every clinic visit while therapy is changing; at least every 3–6 months once stable). Record item-level changes, not just the total. [4]
• Keep a short symptom diary (including fatigue patterns, sleep quality, pruritus triggers, and splenic symptoms) to clarify fluctuations between visits. Use diary data to populate the TSS. [1]

Triage by symptom type and severity

• High TSS or rapidly worsening symptoms: arrange expedited hematology review to consider disease-directed therapy (JAK inhibitor, interferon, or cytoreduction). [2]
• Dominant splenic symptoms (early satiety, left-upper belly pain): assess spleen size (exam ± imaging) and consider JAK inhibitor referral when symptoms impair intake or function. [2]
• Severe pruritus or erythromelalgia: try first-line symptomatic measures (cooling, topical emollients, and a short trial of antihistamines) and consider low-dose aspirin or cytoreduction if microvascular symptoms persist. [1]

Medication and therapy checklist

• Verify indications/reasons to use or avoid a medicine before starting symptom-directed drugs (SSRIs for pruritus, gabapentin for neuropathic pain, low-dose aspirin for microvascular symptoms). Coordinate with hematology when initiating cytoreductive or JAK-directed therapy. [1][2]
• Reassess symptom response 4–12 weeks after any treatment change using the same TSS instrument; document both benefits and adverse effects. [4]

Non-drug and supportive measures

• Encourage graded physical activity, sleep hygiene, and nutritional counseling for appetite/satiety issues, and refer to physiotherapy or occupational therapy for functional limitations. [5]
• Provide psychosocial support and screen for anxiety/depression; offer CBT/referral to mental-health services when cognitive fog or mood symptoms affect function. [1]

Special populations & comorbidity adjustments

• Adolescents or young adults: address fertility, education/work impacts, and tailor supportive services and counseling to their needs; use age-appropriate symptom framing. [3]
• Chronic kidney disease: adjust drug choices/doses and recognise additive fatigue and bleeding/thrombotic risks; involve nephrology for complex cases. [6]

Warning signs—call emergency services requiring urgent attention

New or sudden one-sided limb swelling/pain, chest pain, sudden severe headache, sudden weakness, trouble speaking, face droop, new vision loss, or rapidly progressive splenic pain, urgent evaluation for thrombosis, hemorrhage, or acute complications is indicated. [2]

Documentation & communication

Record TSS, targeted interventions, and patient-reported benefit in the medical record. Share a one-page symptom summary with primary-care teams to coordinate blood pressure, cholesterol, diabetes care, stopping smoking, and supportive care. [4][2]

Consistent use of this checklist, combined with validated symptom scoring and guideline-driven treatment thresholds, optimises identification of treatable problems, times escalation appropriately, and reduces the overall burden of myeloproliferative neoplasms symptoms. [1]

Several priorities will improve understanding and management of myeloproliferative neoplasms symptoms and close current evidence gaps:

• Big databases that collect the same symptom questions. Standardized collection of MPN-SAF/MPN-10 and modified TSS across registries and healthcare systems will enable robust real-world estimates of symptom trajectories, treatment responses, and disparities in care. Linking symptom data with hard clinical outcomes (thrombosis, progression, survival) will clarify which symptom-targeted interventions change long-term prognosis. [4][2]
• Prospective trials with patient-reported outcomes as key endpoints. Trials that place validated symptom scores and quality-of-life measures alongside traditional hematologic and survival endpoints are needed to show the durable benefit of new agents (for example, long-acting interferons, novel JAK inhibitors) on daily functioning and well-being. [5][2]
• Biomarker-driven personalization of symptom-directed care. Research into molecular and inflammatory biomarkers (JAK2 allele burden, cytokine profiles) may allow prediction of symptom patterns and targeted selection of therapies most likely to reduce individual burden. Prospective validation is required before routine clinical use. [1]
• Integrative, multidisciplinary intervention studies. Randomized and pragmatic studies of exercise programs, sleep and cognitive-behavioral interventions, nutritional strategies, and combined medical–psychosocial models will quantify the non-pharmacological benefits and guide scalable supportive care pathways. [5]
• Special-population research. Focused studies in adolescents/young adults, as well as in patients with significant comorbidities (for example, chronic kidney disease), are needed to adapt symptom tools, define age- and comorbidity-specific management strategies, and improve outcomes across diverse patient groups. [3][6]
• Implementation and equity science. Investigation into barriers to routine symptom measurement, access to JAK inhibitors and interferon formulations, and economic analyses will support equitable translation of symptom-focused advances into everyday practice. [2][5]

Advancing these areas will strengthen the evidence base for symptom-centered care, enable the personalization of interventions, and ensure that meaningful gains align with improvements in patients’ day-to-day quality of life. [1][4]

1. What are the symptoms of myeloproliferative neoplasms?

Myeloproliferative neoplasms (MPNs) commonly cause fatigue, night sweats, unintentional weight loss, itching (often after warm showers), headaches, visual changes, burning/redness in hands or feet (erythromelalgia), early fullness from an enlarged spleen, and bone pain. Symptoms vary from person to person and may come and go.

2. Why do MPNs cause so many different symptoms?

Symptoms arise from inflammation, changes in blood counts/viscosity, spleen or liver enlargement, and bone-marrow changes such as fibrosis. Some medications can also affect your overall well-being.

3. Which symptoms are most common in polycythemia vera (PV)?

Aquagenic pruritus (intense itching after hot water), headaches, visual changes, and erythromelalgia are typical. Many of these improve when red cell and platelet counts are controlled.

4. Which symptoms are most common in essential thrombocythemia (ET)?

Microvascular symptoms, such as headache, lightheadedness, visual blurring, and erythromelalgia, are frequent. Some people also have easy bruising or mucosal bleeding if platelet function is abnormal.

5. Which symptoms are most common in myelofibrosis (MF)?

Constitutional symptoms (fatigue, fevers, night sweats, weight loss) and spleen-related issues (early satiety, abdominal fullness, left-upper-quadrant discomfort) often dominate.

6. How are myeloproliferative neoplasms symptoms measured?

Clinics use short, validated questionnaires such as the MPN-SAF/MPN-10 and the modified Total Symptom Score (TSS). You rate items such as fatigue, itching, night sweats, concentration, bone pain, and early satiety; higher totals indicate a greater symptom burden.

7. Why does routine symptom scoring matter?

Regular use of the same tool tracks change over time, helps your care team see hidden problems, and guides decisions, such as when to adjust therapy or add supportive care.

8. Are there non-drug strategies for myeloproliferative neoplasms symptoms?

Yes, graded exercise, sleep and nutrition support, stress-reduction/CBT, and attention to other conditions (like kidney disease) can meaningfully improve fatigue, mood, and day-to-day function.

9. Do adolescents and young adults experience different issues?

They can have typical physical symptoms plus additional psychosocial, school/work, and fertility concerns. Tools and support often need to be customized to meet specific needs.

1. Tremblay, D., & Mesa, R. (2022). Addressing symptom burden in myeloproliferative neoplasms. Best Practice & Research Clinical Haematology, 35(2), 101372.
2. https://www.sciencedirect.com/science/article/pii/S1521692622000275
3. Gerds, A. T., Gotlib, J., Ali, H., Bose, P., Dunbar, A., Elshoury, A., ... & Hochstetler, C. (2022). Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 20(9), 1033–1062.
4. https://jnccn.org/view/journals/jnccn/20/9/article-p1033.xml?ArticleBodyColorStyles=inline%20pdf
5. Goulart, H., Masarova, L., Mesa, R., Harrison, C., Kiladjian, J. J., & Pemmaraju, N. (2024). Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. British Journal of Haematology, 205(1), 48–60.
6. https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.19557
7. Langlais, B. T., Mazza, G. L., Kosiorek, H. E., Palmer, J., Mesa, R., & Dueck, A. C. (2021). Validation of a modified version of the myeloproliferative neoplasm symptom assessment form Total symptom score. Journal of Hematology, 10(5), 207.
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC8577588/
9. Andreazzoli, F., Levy Yurkovski, I., Gowin, K., & Bonucci, M. (2025). Management of Myeloproliferative Neoplasms: An Integrative Approach. Journal of Clinical Medicine, 14(14), 5080.
10. https://www.mdpi.com/2077-0383/14/14/5080
11. Holik, H., Lucijanic, M., & Krecak, I. (2023). Specific symptom burden in patients with chronic myeloproliferative neoplasms and chronic kidney disease. Annals of Hematology, 102(7), 1963–1965.